Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series
Therapeutic Apheresis and Dialysis · 2024-06 · 28 (3) · 432-441
DOI: 10.1111/1744-9987.14106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 15.01.2024. Verfasst von Tomoka Watanabe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Dermatomyositis, Plasma Exchange, Interferon-Induced Helicase, IFIH1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Clinically amyopathic dermatomyositis (CADM) with anti‐melanoma differentiation‐associated gene 5 (MDA5) antibody (Ab) with rapidly progressive interstitial lung disease (RP‐ILD) is often refractory for intensive immunosuppression. In this study, we verified the effectiveness and safety of plasma exchange (PEx) for this lethal disease.
Methods
We retrospectively examined the clinical course and adverse effect (AE) of 12 patients with anti‐MDA5 Ab–positive CADM between January 2017 and December 2021 in our hospital.
Results
Five out of six patients treated with simple PEx using fresh frozen plasma or 5% albumin survived with or without home oxygen therapy. Multiple PEx (15–20 times) were required to achieve satisfactory improvement as well as remission of CADM. The AEs caused by PEx were resolved using conventional methods.
Conclusion
PEx might be a promising option for controlling the disease activity of anti‐MDA5 Ab–positive CADM with severe RP‐ILD and may contribute to better survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
- Department of Clinical Engineering, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
- Department of Immunology, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan.
ORCID-Profile: Tatsuo Tsukamoto
Zitieren
APA
Watanabe, T., Taniguchi, M., Ogura, S., Asou, M., Takayanagi, S., Sokai, Y., Tsuji, Y., Mori, K. P., Endo, T., Nakajima, T., Imura, Y., & Tsukamoto, T. (2024). Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series. Therapeutic Apheresis and Dialysis, 28(3), 432-441. https://doi.org/10.1111/1744-9987.14106
Vancouver
Watanabe T, Taniguchi M, Ogura S, Asou M, Takayanagi S, Sokai Y, et al. Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series. Therapeutic Apheresis and Dialysis. 2024;28(3):432-441. doi:10.1111/1744-9987.14106
BibTeX
@article{Watanabe2024,
author = {Watanabe, Tomoka and Taniguchi, Misaki and Ogura, Sanae and Asou, Mea and Takayanagi, Shunsuke and Sokai, Yuko and Tsuji, Yoshiki and Mori, Keita P and Endo, Tomomi and Nakajima, Toshiki and Imura, Yoshitaka and Tsukamoto, Tatsuo},
title = {Effectiveness and safety of plasma exchange for anti‐MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: A case series},
journal = {Therapeutic Apheresis and Dialysis},
year = {2024},
volume = {28},
number = {3},
pages = {432--441},
doi = {10.1111/1744-9987.14106}
}
EUVIMED